Our Q1 2020 report includes our first ever historical price and patient dose analysis combining data from our previous publications to show long-term market trends. We have found the number of products available for doctors to prescribe has now reached 100. Product prices have continued their downward trend and are now 17.4% cheaper on average than reported in Q3 2019. Patients have also reported significantly increasing their average daily dose, possibly due to price declines making higher doses more affordable.
It seems possible that CBD will become available for behind the counter pharmacy sales. But the path to market will be challenging for many cannabis companies. December 2019 saw an annualised product sales run rate of nearly $50M. FreshLeaf expects that by December 2020 this will have nearly tripled to around $150M.